Clinical Trial Update: Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis [Phase 3]

View source ↗

Summary

Phase 3 trial assessing biosimilar denosumab (GP2411) in postmenopausal osteoporosis completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• GP2411 (biosimilar denosumab) (denosumab)

Snippet

Sponsor: Sandoz | Conditions: Postmenopausal Women With Osteoporosis | Phase 3 | Status: COMPLETED | Results posted: 2023-03-08